These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 32648688)
1. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a. Du H; Li Y; Sun R; Yuan Y; Sun S; Zhang Y Thorac Cancer; 2020 Sep; 11(9):2473-2482. PubMed ID: 32648688 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6. Ge X; Jiang Y; Hu X; Yu X Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003 [TBL] [Abstract][Full Text] [Related]
3. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma. Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670 [TBL] [Abstract][Full Text] [Related]
5. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342 [TBL] [Abstract][Full Text] [Related]
6. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma. Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178 [TBL] [Abstract][Full Text] [Related]
7. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669 [TBL] [Abstract][Full Text] [Related]
8. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053 [TBL] [Abstract][Full Text] [Related]
9. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data. Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058 [TBL] [Abstract][Full Text] [Related]
10. MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1. Su C; Cheng X; Li Y; Han Y; Song X; Yu D; Cao X; Liu Z Cancer Med; 2018 Jun; 7(6):2485-2503. PubMed ID: 29663730 [TBL] [Abstract][Full Text] [Related]
11. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma. Zhang Y; Du H; Li Y; Yuan Y; Chen B; Sun S Cancer Sci; 2020 Feb; 111(2):637-646. PubMed ID: 31677335 [TBL] [Abstract][Full Text] [Related]
12. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway. Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754 [TBL] [Abstract][Full Text] [Related]
13. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2. Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878 [TBL] [Abstract][Full Text] [Related]
14. miR-195-5p inhibits cisplatin resistance in lung adenocarcinoma by regulating DNA damage via targeting E2F7. Wu H; Zheng B J Biochem Mol Toxicol; 2024 Nov; 38(11):e70015. PubMed ID: 39415701 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line. Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998 [TBL] [Abstract][Full Text] [Related]
16. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells. He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma. Son SM; Yun J; Kim DW; Jung YS; Han SB; Lee YH; Han HS; Woo CG; Lee HC; Lee OJ BMC Cancer; 2023 Sep; 23(1):843. PubMed ID: 37684602 [TBL] [Abstract][Full Text] [Related]
18. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). Wang H; Zhu LJ; Yang YC; Wang ZX; Wang R Br J Cancer; 2014 Jul; 111(2):339-54. PubMed ID: 24921914 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110 [TBL] [Abstract][Full Text] [Related]
20. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]